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Abstract: Background: High intake of cereal fibre is associated with reduced risk for type 2 diabetes 
and long-term complications. Within the first long-term randomized controlled trial specifically 
targeting cereal fibre, the Optimal Fibre Trial (OptiFiT), intake of insoluble oat fibre was shown to 
significantly reduce glycaemia. Previous studies suggested that this effect might be limited to 
subjects with impaired fasting glucose (IFG). Aim: We stratified the OptiFiT cohort for normal and 
impaired fasting glucose (NFG, IFG) and conducted a secondary analysis comparing the effects of 
fibre supplementation between these subgroups. Methods: 180 Caucasian participants with 
impaired glucose tolerance (IGT) were randomized to twice-a-day fibre or placebo 
supplementation for 2 years (n = 89 and 91, respectively), while assuring double-blinded 
intervention. Fasting blood sampling, oral glucose tolerance test and full anthropometry were 
assessed annually. At baseline, out of 136 subjects completing the first year of intervention, 72 (54 
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%) showed IFG and IGT, while 64 subjects had IGT only (labelled “NFG”). Based on these two 
groups, we performed a stratified per-protocol analysis of glycometabolic and secondary effects 
during the first year of intervention. Results: The NFG group did not show significant differences 
between fibre and placebo group concerning anthropometric, glycometabolic, or other biochemical 
parameters. Within the IFG stratum, 2-h glucose, HbA1c, and gamma-glutamyl transferase levels 
decreased more in the fibre group, with a significant supplement x IFG interaction effect for 
HbA1c. Compared to NFG subjects, IFG subjects had larger benefits from fibre supplementation 
with respect to fasting glucose levels. Results were robust against adjustment for weight change 
and sex. An ITT analysis did not reveal any differences from the per-protocol analysis. 
Conclusions: Although stratification resulted in relatively small subgroups, we were able to 
pinpoint our previous findings from the entire cohort to the IFG subgroup. Cereal fibre can 
beneficially affect glycemic metabolism, with most pronounced or even isolated effectiveness in 
subjects with impaired fasting glucose. 
Keywords: diabetes mellitus type 2; prediabetes; diabetes prevention; impaired fasting glucose; 
stratification; impaired glucose tolerance; insoluble dietary fibre; insulin sensitivity 
 
1. Introduction 
The worldwide prevalence of Type 2 diabetes mellitus (T2DM) is rising quickly. T2DM 
accounts for a huge proportion of patients with premature death and morbidity, leading to 
cardiovascular disease, cancer, and other long-term complications. Although about 50% of the 
disorder can be explained by genetic influences, T2DM onset and progression are also widely 
modulated by eating behaviour, physical activity, and other factors of a healthy lifestyle. Prevention 
and therapy of T2DM are therefore based on these elements and several large prevention trials have 
demonstrated their enormous potential; total risk reduction of diabetes incidence of about 40%–60% 
was consistently possible [1–4].  
Besides overeating and obesity, some specific nutritional factors have been identified in 
epidemiological studies, such as high intake of saturated fat, absence or overconsumption of alcohol 
and low intake of dietary fibre [5]. These factors are usually addressed jointly in order to facilitate 
the most effective prevention. In Germany, the PREDIAS scheme was developed on this basis. It 
entails a one-year course with an intensified first phase followed by a second maintenance phase 
with moderate counselling intensity, including various counselling techniques, which addresses 
different dietary aspects [6].  
The Optimal Fibre Trial (OptiFiT), first published in 2018, was the first large, long-term, 
randomized controlled trial (RCT) investigating the effects of insoluble cereal fibre. OptiFiT was 
conducted in subjects with a high risk of diabetes. Although cohort studies have pointed to cereal 
fibre already more than a decade before, there is still lack of interventional proof that 
nonfermentable dietary fibre from grains and legumes is in fact improving metabolic state. OptiFiT 
demonstrated a very small effect on HbA1c as a secondary outcome, while the primary outcome on 
diabetes incidence was not achieved and 2-h glucose levels only reached statistical significance in 
women [7].  
Recently, several publications highlighted, that T2DM is not a homogenous metabolic disorder. 
Cohort studies on new-onset T2DM patients discovered several phenotype clusters, distinguishing 
patients with mild metabolic disturbance from subjects with higher risk of complications on the 
basis of very simple anthropometric or metabolic parameters. Within these clusters, glycaemic state 
is a major component of cluster definitions [8,9].  
Such stratification techniques are also relevant for intervention studies, as various 
(pre-)diabetes subgroups may respond differently to prevention and therapy. There is evidence that 
fasting glucose levels affect the metabolic benefit from a diet with low glycaemic index [10]. 
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Fibre-rich diets may explicitly improve glycaemic outcomes in subjects with impaired fasting 
glucose (IFG) [11]. 
We therefore decided to perform a stratified analysis of the Optimal Fibre Trial based on 
pretreatment glycaemic state. We hypothesize that subjects with IFG experience a stronger benefit 
from one year of fibre supplementation than subjects with normal fasting glucose. 
2. Research Design and Methods 
The recruitment, inclusion, and exclusion criteria, as well as the overall study design, have been 
published elsewhere [7]. The Optimal Fibre Trial recruited 180 subjects with impaired glucose 
tolerance (IGT) in order to investigate subjects with an increased risk of diabetes onset. Most of the 
subjects additionally fulfilled the definition of Metabolic Syndrome. 136 subjects completed the first 
year of intervention and thus formed the per-protocol dataset. 
For the presented work, the cohort was stratified by baseline glycaemic state, resulting in 72 
subjects with combined IFG and impaired glucose tolerance (IGT) and 64 with normal fasting 
glucose (NFG) and IGT. IFG was defined by capillary glucose levels above 90.0 mg/dl. 
All participants started the 24 month study with the one-year lifestyle program PREDIAS, 
which is a structured “Treatment and Education Program for Prevention of Type 2 Diabetes” [12]. It 
contained group-based consultations at regular intervals and consisted of 12 individual 2 hr lessons 
divided into a core intervention (8 lessons in 8 weeks) and booster sessions (4 lessons throughout the 
following 10 months) [6].  
We further specified our dietary approach, differing from the dietary targets of the original 
PREDIAS publication. We defined goals for change in diet quality that subjects were asked to fulfil. 
These goals were in accordance with the recommendations of the German Society for Nutrition 
(DGE): fat intake below 30 kcal%, intake of saturated fat below 10 kcal%, and intake of dietary fibre 
above 15 g/1000 kcal. We also aimed for higher levels of physical activity (240 min/week) than the 
original PREDIAS recommendation (150 min/week).[6] We recommended frequent ingestion of 
whole-grain products, legumes, vegetables, fruits, in particular berries, milk and meat products with 
low fat content, soft margarines, and vegetable oils rich in unsaturated fatty acids. Pedometers and 
the European Physical Activity Questionnaire (EPAQ)-2 were used in order to monitor physical 
activity (PA) [13].  
Our participants completed food records for four consecutive days, including one weekend 
day, at baseline, and every six months from that. Nutrient intake was determined using the nutrition 
software PRODI® 5.8 (Nutri-Science, Hausach, Baden-Wuerttemberg, Germany) based on 
Bundeslebensmittelschlüssel 3.0 [14].  
Parallel to the PREDIAS dietary consultation, all participants received a drinking supplement, 
which should be used for the entire year and for an additional year after discontinuation of 
PREDIAS. Thus, supplementation lasted for 24 months. 
2.1. Dietary Supplement 
Details on the supplementation procedure, measurements and laboratory parameters have 
been given elsewhere [7]. All participants were provided with drinking supplements containing 
either a purified fibre extract derived from oat hulls (“fibre”; 70 wt% cellulose, 25 wt% hemicellulose 
and 3–5 wt% lignin (Vitacel OF 560-30; Rettenmaier & Söhne, Holzmuehle, Germany)) or a waxy 
maize starch with negligible content of insoluble fibre and guar gum and isomaltulose (“placebo”). 
Supplements should be consumed twice-a-day after dissolving the recommended amount of 
drinking powder in 300 mL of water. The fibre supplement added 15 g of mainly insoluble fibre per 
day (7.5 g per serving) to the normal nutrition. Both supplements were similar in appearance, taste, 
odour, and texture. Allocation was blinded to both participants and study personnel. Supplement 
tins were weighed accurately before distribution and weighed again when returned after use at the 
main visits. 
Randomisation to fibre or placebo supplementation led to the formation of the following 
subgroups: NFG fibre (n = 32), NFG placebo (n = 32); IFG fibre (n = 35), IFG placebo (n = 37). 
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2.2. Calculations 
Areas under the curve (AUC) for oral glucose tolerance test (OGTT) responses (plasma glucose, 
insulin, and C-peptide) were calculated by the trapezoidal method. Insulin resistance was 
determined by the homeostasis model assessment (HOMA-IR) [15], the ISIffa [16], and dynamic 
insulin sensitivity indices, described by Belfiore, Aloulou, and Cederholm [16–18]. We also 
calculated the fatty liver index (FLI) [19]. 
2.3. Statistical Analyses 
We used the Kolmogorov–Smirnov test in order to determine normal distribution of our data. 
Given frequent absence of normal distribution, we decide to conduct nonparametric tests all over the 
trial to ensure uniform representation, Mann–Whitney tests for cross-sectional comparisons and 
Wilcoxon tests for longitudinal comparisons. In case of significant differences between groups, a 
3-way ANOVA (mixed linear model: time x diet x IFG baseline status) was conducted. Adjustments 
for weight change and sex were included to account for possible group differences. All data are 
presented as means ± standard deviation. The results were considered significantly different if p < 
0.05. All statistical analyses were performed using SPSS for Windows program version 22.0 (SPSS 
Inc, Chicago, IL, USA).  
3. Results 
Sex distribution differed between both NFG subgroups. Besides that, there were no differences 
in baseline characteristics between the respective fibre groups and their placebo counterparts for the 
NFG (Table 1) and IFG strata (Table 2). IFG subjects were characterized by more strongly deranged 
levels of fasting glucose, body weight, measures of fasting and dynamic insulin resistance 
(HOMA-IR and Belfiore Index), fatty liver index, uric acid, and inflammatory parameters at baseline. 
Table 1. Characteristics of participants at study entry (normal fasting glucose (NFG) subgroups 
only). 
 NFG Fibre NFG Placebo 
Sex w/m 24/8 (75% female) 16/16 (50% female) * 
Age (years) 61.3 ± 9.5 60.3 ± 10.5 
BMI (kg/m²) 31.3 ± 5.7 32.1 ± 5.3 
Weight (kg) 84.7 ± 17.8 89.4 ± 17.0 
Waist circumference (cm) 100.7 ± 15.4 105.2 ± 12.2 
Hip circumference (cm) 111.8 ± 12.8 111.8 ± 12.8 
Waist-to-hip-ratio (WHR) 0.90 ± 0.08 0.94 ± 0.10 
BIA – Body fat (%) 36.8 ± 7.4 36.8 ± 7.8 
 RR syst. (mmHg) 142 ± 19 141 ± 13 
Fasting glucose (mg/dl) 81.7 ± 6.4 82.8 ± 5.5 
2-h glucose (mg/dl) 153.4 ± 13.3 156.3 ± 15.1 
HbA
1c
 (%) 5.5 ± 0.4 5.5 ± 0.3 
Fasting Insulin (mU/l) 8.0 ± 4.7 8.7 ± 3.5 
Fasting C-Peptide (µg/l) 1.4 ± 0.5 1.4 ± 0.5 
HOMA-IR 2.0 ± 1.3 2.2 ± 0.9 
QUICKI 0.36 ± 0.04 0.35 ± 0.03 
ISI
ffa
 0.87 ± 0.34 0.83 ± 0.24 
Belfiore  0.68 ± 0.27 0.69 ± 0.27 
HIC
c-peptide 
(mU/µg) 4.8 ± 1.8 4.8 ± 1.4 
HDL cholesterol (mmol/l) 1.3 ± 0.3 1.3 ± 0.3 
LDL cholesterol (mmol/l) 3.8 ± 0.8 3.5 ± 0.6 
CRP (mg/l) 3.6 ± 5.4 3.1 ± 3.2 
Leukocyte count (Gpt/l) 5.61 ± 1.72 4.96 ± 0.91 
Uric acid (µmol/l) 320 ± 58 347 ± 79 
GGT (U/l) 32 ± 42 37 ± 36 
Fatty liver index (FLI) 62 ± 29 68 ± 29 
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Characteristics of NFG participants at study entry, *Significant difference between the groups, * p < 
0.05. 
Table 2. Characteristics of participants at study entry (impaired fasting glucose (IFG) subgroups 
only). 
 IFG Fibre IFG Placebo 
Sex 24 / 11 (69 % female) 20 / 17 (54 % female) 
Age (years) 58.9 ± 9.1 59.7 ± 8.1 
BMI (kg/m²) 32.2 ± 4.6 34.5 ± 7.4 
Weight (kg) 90.3 ± 12.7 97.9 ± 23.1 
Waist circumference (cm) 104.0 ± 9.4 108.2 ± 16.4 
Hip circumference (cm) 111.3 ± 10.1 116.8 ± 14.0 
Waist-to-hip-ratio (WHR) 0.94 ± 0.08 0.93 ± 0.09 
BIA – Body fat (%) 37.0 ± 9.2 34.8 ± 8.4 
RR syst. (mmHg) 137 ± 16 142 ± 19 
Fasting glucose (mg/dl) 97.7 ± 6.6 99.0 ± 6.4 
2-h glucose (mg/dl) 161.8 ± 18.0 165.5 ± 20.8 
HbA
1c
 (%) 5.7 ± 0.4 5.7 ± 0.4 
Fasting Insulin (mU/l) 9.9 ± 4.2 10.8 ± 6.5 
Fasting C-Peptide (µg/l) 1.9 ± 0.8 1.8 ± 0.8 
HOMA-IR 2.7 ± 1.2 3.1 ± 2.1 
QUICKI 0.33 ± 0.02 0.34 ± 0.04 
ISI
ffa
 0.85 ± 0.24 0.81 ± 0.34 
Belfiore  0.63 ± 0.27 0.64 ± 0.31 
HIC
c-peptide 
(mU/µg) 5.0 ± 1.6 5.2 ± 2.4 
HDL cholesterol (mmol/l) 1.2 ± 0.2 1.2 ± 0.3 
LDL cholesterol (mmol/l) 3.7 ± 1.0 3.5 ± 0.8 
CRP (mg/l) 5.2 ± 4.1 3.1 ± 4.0 
Leukocyte count (Gpt/l) 5.87 ± 1.29 5.82 ± 1.63 
Uric acid (µmol/l) 358 ± 84 351 ± 85 
GGT (U/l) 37 ± 26 29 ± 22 
Fatty liver index (FLI) 74 ± 21 71 ± 27 
Characteristics of IFG participants at study entry, No significants differences between the groups. 
Intake of calories, macronutrients, and dietary fibre from conventional food did not differ 
between the four subgroups at baseline after one year. Overall, the dietary intake of calories and 
total fat decreased in all four subgroups, while alcohol intake decreased significantly in all but the 
IFG placebo group, and protein intake decreased only in the NFG fibre group. However, there were 
no differences between the four groups concerning dietary changes. Neither did PA change in any of 
the four subgroups, nor were there differences between the changes of PA of any group (Table 3). 
Average fibre intake by supplementation was 1 ± 0 g in the placebo groups and 13 ± 2 g in the 
fibre groups. 
Table 3. Lifestyle habits at baseline and after one year of intervention. 
 
NFG 
Fibre 
(Baseline) 
NFG 
Placebo 
(Baseline) 
IFG Fibre 
(Baseline) 
IFG 
Placebo 
(Baseline) 
NFG 
Fibre 
(12 
Months) 
NFG 
Placebo 
(12 
Months) 
IFG 
Fibre 
(12 
Months) 
IFG 
Placebo 
(12 
Months) 
Food intake 
Total energy 
intake (kcal/day) 
1970 ± 386 2054 ± 626  2118 ± 532  1969 ± 541  
1698 ± 
414 * 
1888 ± 
469 * 
1772 ± 
360 * 
1933 ± 
607 * 
Fat intake (g/day) 75 ± 22 78 ± 26  85 ± 26  79 ± 31  64 ± 24 * 70 ± 26 * 66 ± 21* 73 ± 32 * 
Protein intake 
(g/day) 
78 ± 18  82 ± 23 85 ± 26 84 ± 22 66 ± 17 ** 81 ± 21 75 ± 21 81 ± 23 
Carbohydrate 
intake (g/day) 
226 ± 52 231 ± 82 227 ± 63 214 ± 57 205 ± 45 216 ± 47 201 ± 44 220 ± 63 
Total dietary 
fibre intake 
(g/day) 
23 ± 6 25 ± 9 23 ± 8 22 ± 5 23 ± 6 24 ± 10 22 ± 8 24 ± 8 
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Insoluble 15 ± 4 16 ± 6 15 ± 5 15 ± 4 15 ± 5 16 ± 5 14 ± 5 15 ± 5 
Soluble 7 ± 2 8 ± 3 7 ± 2 7 ± 2 7 ± 2 8 ± 3 7 ± 2 7 ± 2 
Alcohol (g/day) 8 ± 16 11 ± 15  12 ± 15  6 ± 12  3 ± 4 * 7 ± 8 * 8 ± 10 * 7 ± 13  
Physical activity 
Steps per day 
7052 ± 
2924 
6045 ± 2472 
6382 ± 
3063 
6482 ± 
2711 
7775 ± 
3348 
5805 ± 
2601 
7185 ± 
3215 
7538 ± 
3795 
Energy 
expenditure by 
steps 
499 ± 218 400 ± 160 415 ± 243 461 ± 278 534 ± 247 381 ± 188 435 ± 160 508 ± 239 
Changes in lifestyle habits during intervention; supplement intake is not covered by this assessment. 
Nutrient intakes were calculated from four-day food records. Physical activity was derived from 
one-week assessments with pedometers. Data are means (SD). * Significant change within the 
groups, * p < 0.05. 
The two NFG groups did not differ with regard to the change of anthropometric or metabolic 
parameters over the one-year intervention period. The NFG fibre group exclusively experienced a 
significant decline in hip circumference, blood pressure, and an increase in fasting glucose. The NFG 
placebo group, but not its fibre counterpart, showed a significant decrease in waist-to-hip ratio 
(WHR) and quantitative insulin sensitivity check index (QUICKI). Within both NFG subgroups, 
significant improvements were detected for body weight, waist circumference, 2-h glucose levels, 
ISIffa, Belfiore index, hepatic insulin clearance (HIC), and fatty liver index (FLI). (Table 4) 
Table 4. Changes in anthropometric and metabolic parameters. 
  
NFG 
Fibre 
NFG 
Placebo 
IFG 
Fibre 
IFG 
Placebo 
NFG: Fibre 
vs. Placebo 
IFG: Fibre 
vs. Placebo 
Placebo: 
NFG vs. 
IFG 
Fibre: 
NFG vs. 
IFG 
Weight (kg) 
−3.2 ± 
5.3 ** 
−3.1 ± 5.5 
** 
−2.2 ± 
3.8 *** 
−3.1 ± 5.9 
** 
n.s. n.s. n.s. n.s. 
Waist 
circumference 
(cm) 
−2.9 ± 
5.8 ** 
−3.5 ± 7.4 
* 
−2.9 ± 
4.5 *** 
−3.1 ± 6.0 
** 
n.s. n.s. n.s. n.s. 
Hip 
circumference 
(cm) 
−3.2 ± 
4.0 *** 
−1.3 ± 4.3 −1.5 ± 
4.7 
−3.8 ± 5.9 
** 
n.s. n.s. n.s. n.s. 
WHR 
0.00 ± 
0.04 
−0.02 ± 
0.05 * 
−0.01 ± 
0.04 
0.00 ± 
0.05 
n.s. n.s. n.s. n.s. 
BIA – Body fat 
(%) 
−0.4 ± 
5.1 
−2.2 ± 5.8 −0.6 ± 
4.3 
−0.2 ± 3.1 n.s. n.s. n.s. n.s. 
 RR syst. 
(mmHg) 
−7 ± 16 
* −2 ± 15 2 ± 16 −2 ± 19 n.s. n.s. n.s. n.s. 
Fasting glucose 
(mg/dl) 
4.3 ± 
9.8 * 
2.7 ± 7.7 
−7.6 ± 
8.8 *** 
−4.7 ± 7.6 
** 
n.s. n.s. † < 0,001 † < 0,001 
2-h glucose 
(mg/dl) 
−9.5 ± 
24.1 * 
−11.6 ± 
23.8 ** 
−12.7 ± 
33.3 ** 
1.8 ± 34.9 n.s. † < 0,05 † < 0,05 n.s. 
HbA
1c
 (%) 0.1 ± 
0.5 
−0.0 ± 0.4 −0.1 ± 
0.4 
0.2 ± 0.6 * n.s. † < 0,01 † < 0,05 n.s. 
Fasting Insulin 
(mU/l) 
−1.2 ± 
3.2 
−0.4 ± 4.3 −1.8 ± 
3.6 ** 
1.8 ± 5.2 * n.s. n.s. n.s. n.s. 
Fasting 
C-Peptide (µg/l) 
0.1 ± 
1.0 
0.4 ± 1.3 0.1 ± 1.4 0.4 ± 1.6 n.s. n.s. n.s. n.s. 
HOMA-IR 
−0.3 ± 
0.9 
−0.1 ± 1.2 −0.6 ± 
1.2 ** 
−0.6 ± 1.5 
* 
n.s. n.s. n.s. n.s. 
QUICKI 
0.00 ± 
0.03 
0.01 ± 
0.03 * 
0.01 ± 
0.02 ** 
0.01 ± 
0.03 * 
n.s. n.s. n.s. n.s. 
ISI
ffa
 0.10 ± 
0.27 * 
0.10 ± 
0.25 * 
0.04 ± 
0.28 
0.09 ± 
0.38 
n.s. n.s. n.s. n.s. 
Belfiore  
0.12 ± 
0.30 * 
0.11 ± 
0.27 * 
0.14 ± 
0.27 ** 
0.16 ± 
0.24 ** 
n.s. n.s. n.s. n.s. 
HIC
c-peptide 
(mU/µg) 
1.0 ± 
2.2 * 
1.2 ± 2.3 
** 
1.3 ± 2.6 
** 
1.9 ± 2.5 
*** 
n.s. n.s. n.s. n.s. 
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HDL cholesterol 
(mmol/l) 
−0.0 ± 
0.2 
−0.0 ± 0.2 0.0 ± 0.1 0.0 ± 0.3 n.s. n.s. n.s. n.s. 
LDL cholesterol 
(mmol/l) 
−0.1 ± 
0.5 
−0.1 ± 0.8 −0.1 ± 
1.0 
−0.2 ± 0.9 n.s. n.s. n.s. n.s. 
CRP (mg/l) 
−0.5 ± 
4.2 
−0.6 ± 2.6 −1.8 ± 
3.3 ** 
−0.5 ± 2.8 n.s. n.s. n.s. n.s. 
Leukocyte count 
(Gpt/l) 
−0.33 ± 
1.41 
0.19 ± 
1.03 
−0.65 ± 
1.14 * 
−0.07 ± 
1.04 
n.s. n.s. n.s. n.s. 
Uric acid 
(µmol/l) 
−7 ± 43 −11 ± 61 −14 ± 69 −6 ± 55 n.s. n.s. n.s. n.s. 
GGT (U/l) −8 ± 40 −4 ± 20 −5 ± 14 6 ± 24 n.s. † < 0,05 n.s. n.s. 
Fatty liver index 
(FLI) 
−8 ± 17 
* 
−7 ± 13 ** −5 ± 12 
* 
−2 ± 13 n.s. n.s. n.s. n.s. 
Outcomes during intervention; Mean ± SD. * Significant difference within the groups; * p < 0.05, ** p < 
0.01, *** p < 0.001.; † Significant diﬀerence between groups; n.s. = not significant. 
Within the IFG stratum, 2-h glucose, HbA1c, and gamma-glutamyl transferase (GGT) decreased 
significantly more in the fibre group. These differences also remained significant after adjustment 
for weight change and sex. 2-h glucose, leukocyte count, C-reactive protein (CRP), and FLI improved 
only in the fibre group. HbA1c increased significantly in the placebo group, while there was no 
change in the fibre group. Significant within-group effects for body weight, waist circumference, 
fasting glucose, fasting insulin, HOMAIR, QUICKI, Belfiore index, and HIC were seen in both 
intervention groups of the IFG stratum. (Table 4) 
When comparing NFG and IFG subgroups within the fibre intervention, IFG had a significantly 
larger benefit with respect to 2-h glucose levels. Comparison of NFG and IFG subgroups within the 
placebo arm revealed a significantly stronger benefit for IFG patients with respect to fasting glucose, 
and a significantly stronger improvement of 2-h glucose and HbA1c in the NFG group. The 
interaction effect (time x supplement x IFG status; adjusted for weight change and sex) was 
significant for HbA1c (p = 0,002), but not for fasting glucose, 2-h glucose and GGT. (Table 4) 
There was no difference in drop-out rates: IFG placebo (13/50 = 26 %), IFG fibre (13/48 = 27%), 
NFG placebo (9/41 = 22%), NFG fibre (9/41 = 22%). Intention-to-treat analysis did not lead to different 
results. 
4. Discussion 
As hypothesized, participants with impaired fasting glucose had a stronger benefit from fibre 
supplementation than NFG subjects. Only in IFG subjects, fibre supplementation resulted in 
significantly improved levels of 2-h glucose, GGT, and HbA1c compared to placebo. This led to a 
significant interaction effect for HbA1c, favouring fibre in IFG subjects. IFG subjects had stronger 
reductions of fasting glucose irrespective of supplement allocation in comparison with NFG 
counterparts. Therefore, we did neither find a statistical difference between fibre and placebo for 
fasting glucose, nor a significant interaction based on fasting glucose state and supplement group.  
The Optimal Fibre Trial was the first RCT to investigate long-term effects of cereal insoluble 
fibre (mainly cellulose and hemicellulose) and focused on diabetes onset. The reported effects in the 
original publication were small in magnitude and partially failed to reach statistical significance. In 
this post hoc analysis, we now provide evidence that the borderline effect of the fibre 
supplementation observed in the entire sample was in fact driven by a well-defined subgroup effect. 
The analysed cohort was recruited only by the presence of IGT, which is more common in women. 
IGT is also more strongly linked to impaired insulin secretion and impaired postprandial insulin 
action rather than fasting (hepatic) insulin sensitivity. Those imbalances in the cohort structure may 
somewhat explain the small effect [7]. 
In our current paper, we tried to pinpoint a potential metabolic benefit of cereal fibre to a more 
defined subtype of prediabetes. IFG and fasting insulin resistance rather than IGT and dynamic 
insulin resistance are strongly associated with hepatic insulin resistance and nonalcoholic fatty liver 
disease (NAFLD) [20–22]. Hepatic insulin resistance can only be assessed specifically by conducting 
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isotope-based euglycaemic-hyperinsulinemic clamps. Such data, however, was not available in 
OptiFiT. Also, there was only a small subgroup of patients, whose liver fat content was measured by 
magnetic-resonance spectroscopy (MR-S). Therefore, neither hepatic insulin resistance nor NAFLD 
state could be used to stratify the cohort. Stratification by IFG state led to subgroups of comparable 
size and, most notably, without widespread statistical differences in anthropometric or metabolic 
parameters at baseline between the respective fibre and placebo arms. As expected, IFG subjects 
were characterized not only by higher fasting glucose levels but also by higher body weight, 
measures of fasting and dynamic insulin resistance (HOMA-IR and Belfiore Index), fatty liver index, 
uric acid levels, and inflammatory parameters at baseline. 
The first main finding of this stratified analysis is a replication of the major effects of the 
primary OptiFiT publication. Within the IFG subset, fibre supplementation led to a significantly 
stronger improvement of 2-h glucose levels and HbA1c. These effects were robust after adjustment 
for weight change and sex despite a resulting considerably lower statistical power; for HbA1c, a 
significant interaction effect was found. Thus, the fibre effect goes beyond mere consolidation of 
prediabetic state by actually lowering glucose levels and promoting prediabetes remission. As a 
nonglycaemic outcome, fibre and placebo subgroups in the IFG class also differed in their change of 
GGT levels. This might indicate a possible mode of action. Up to now, the specific processes 
underlying metabolic improvements by cereal fibre intake are not fully understood. Neither 
incretins nor fermentation have so far been consistently identified as crucial factors in most studies 
[23,24]. However, baseline gut microbiota may be a determinant [25]. Data from the ProFiMet Trial 
(Protein, Fibre, Metabolic Syndrome) suggest that insoluble fibre intake promotes the faecal 
excretion of BCAAs, thereby reducing their serum levels. BCAAs are activators of the mTOR 
pathway and may impair insulin sensitivity [26]. However, ProFiMet did not report an effect on 
liver fat content through fibre intake.  
In the NFG subset of OptiFiT no differences were observed between the fibre and placebo 
interventions. Both interventions were accommodated by weight loss and concomitant 
improvement of insulin sensitivity and fatty liver index.  
When comparing the fibre subgroups, IFG subjects showed a larger improvement in fasting 
glucose. As the same observation was done when comparing the placebo subgroups, this is likely to 
be explained by the difference in baseline levels and thereby partly due to regression towards the 
mean.  
Additionally, NFG placebo subjects showed a larger improvement in postprandial glucose and 
HbA1c than IFG placebo subjects, which was not explained by different baseline values. These 
differential changes may possibly be caused by metabolic factors, such as insulin resistance or 
inflammatory state, which were indeed significantly higher in the IFG group. From that perspective, 
IFG placebo subjects would appear to be “resistant” to the lifestyle treatment (PREDIAS) and lacked 
an active supplement. NFG subjects did not benefit from fibre supplementation but at least 
improved by participation in the PREDIAS intervention. Fibre supplementation was apparently 
capable to provide IFG subjects with a benefit in HbA1c and postprandial glucose similar to both 
NFG subsets, although the effect of the PREDIAS intervention was rather limited in the IFG subset. 
We therefore see replicated and pronounced evidence for the glycometabolic benefit of cereal 
fibre in subjects with prediabetes. The specific effect of insoluble fibre rather than soluble fibre needs 
to be investigated more thoroughly [27]. We propose that a possible way of action may be linked to 
the presence of NAFLD, which is often associated with IFG and, in combination with each other, 
leads to a substantially higher risk for diabetes onset [28]. Previous studies have already indicated 
that IFG state may facilitate the beneficial effects of cereal fibre [10,11]. Such interaction effects 
between metabolic state and fibre-driven metabolic improvements have also been reported for 
inulin [29].  
Compared to previous RCTs on dietary fibre, OptiFiT provides several strengths: larger overall 
power, and extensive metabolic phenotyping, as well as the inclusion of both female and male 
subjects. In addition to that, we argue that in comparison to many previous mechanistic studies on 
cereal fibre, several potential confounders can be ruled out in our analysis. Firstly, all four 
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subgroups received the same prediabetes prevention program. Food records of all four groups 
indicate that the PREDIAS program enabled all subgroups to decrease saturated fat intake, leading 
to caloric restriction and weight loss. Reduced intake of saturated fats may explain reduced levels of 
inflammatory parameters, blood pressure, and insulin resistance even in the absence of weight loss 
[30–33]. Furthermore, baseline and change in PA between the four subgroups did not differ, and we 
assume that this element of lifestyle change did not explain differences between the groups. Also, 
there was no difference in weight loss between the respective subgroups. By post-study 
questionnaires we were able to systematically assess side effects of the supplementation. We did not 
find group differences in the frequency of bloating or any other specific gastrointestinal side effect. 
Weight loss was similar in all four groups, and differences in metabolic outcomes between the 
groups remained significant after adjustment for weight change and sex.  
Previous trials on insoluble cereal fibre focused on fibre-rich food, but many studies reported 
poor compliance to the advice for fibre-rich diet [34]. By supplementation, we eliminated this 
problem and determined high compliance in most of our subjects by drug accounting and 
post-study questionnaires. Furthermore, supplementation assured that the metabolic effects can be 
attributed to dietary fibre only and not the whole food matrix, glycaemic index of digestible 
carbohydrates, or vitamins and minerals from whole grain products.  
Assessing compliance is always both crucial and hard, especially in nutritional studies. By 
using four-day food records and continuous drug accounting, we were able to monitor compliance 
to dietary consultation and adherence to supplementation. We did not find evidence for extensive 
underreporting. At any rate, biomarkers for further evaluation of dietary compliance are not 
available. 
Still, our subgroup analysis of OptiFiT itself has to be evaluated under consideration of some 
limitations. There was no preselected definition for specific subgroups, leaving the chance to 
random post hoc significance. However, our results replicated the findings of the original analysis 
quite consistently. 
OptiFiT experienced a one-year drop-out rate of 24%, which is comparable to other lifestyle 
intervention studies [1–4]. Drop-outs due to incident T2DM mainly occurred after the one-year visit, 
therefore not affecting the results of this analysis.  
We are aware that OptiFiT lacks an additional randomized control group without any kind of 
intervention. This option was intentionally excluded for statistical and ethical reasons.  
Further studies should also include an assessment of the gut microbiome. We did not find 
evidence for increased GI side effects, but even low-fermentable fibre as in our supplement might 
influence gut bacteria in some way. 
5. Conclusion 
In conclusion, we demonstrate that supplementation with insoluble cereal fibre leads to a 
glycometabolic improvement (2-h glucose and HbA1c) in subjects with IFG but not with NFG. IFG 
subjects, furthermore, show a significantly larger reduction in GGT levels compared to NFG 
subjects, which might highlight a mechanistic pathway for the glycometabolic effects involving 
NAFLD. The results indicate that NFG subjects mainly benefit from the PREDIAS program, while 
IFG subjects require fibre supplementation to achieve the same metabolic benefit as NFG subjects. 
We provide further evidence that insoluble dietary fibre is a relevant nutritional target for future 
clinical trials. 
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